Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-18
2007-09-18
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S121000
Reexamination Certificate
active
11410343
ABSTRACT:
Disclosed are compounds of the Formula Vand pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, R10, R11and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
REFERENCES:
patent: 6221850 (2001-04-01), McKay et al.
patent: 6310060 (2001-10-01), Barrett et al.
patent: 2003/0004193 (2003-01-01), Barrett et al.
patent: 2003/0045521 (2003-03-01), Tecle
patent: 2003/0078428 (2003-04-01), Barrett et al.
patent: 2003/0092748 (2003-05-01), Barrett et al.
patent: WO 99/01421 (1999-01-01), None
patent: WO 00/41505 (2000-07-01), None
patent: WO 00/41505 (2000-07-01), None
patent: WO 0041994 (2000-07-01), None
Rosenberger, et al.“Macrophages Inhibit Salmonella Typhimurium Replication through MEK/ERK Kinase and Phagocyte NADPH Oxidase Activities”; J. Bio. Chem. May 2002; pp. 18753-18762; vol. 277, No. 21; US.
Blake James
Wallace Eli M.
Array BioPharma Inc.
Freistein Andrew B.
McKane Joseph K.
Moore John R.
LandOfFree
Heterocyclic inhibitors of MEK and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic inhibitors of MEK and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic inhibitors of MEK and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3788940